{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031609","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.053904+00:00","generated_at":"2026-06-08T04:35:10.398905+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CervoMed completes reverse merger, dosed first patient in Phase 2b DLB trial, Q3 cash $10.4M","bullets":["First patient dosed in Phase 2b RewinD-LB study of neflamapimod for dementia with Lewy bodies (DLB).","Completed reverse merger; now publicly traded on Nasdaq under ticker CRVO.","Cash and equivalents $10.4M as of Sep 30, 2023; expects cash runway through end of 2024.","Net income of $2.2M in Q3 2023 vs net loss of $0.9M in Q3 2022, driven by noncash gain from convertible notes conversion.","Topline primary efficacy data from RewinD-LB study expected in second half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031609","json":"https://secwatch.observer/filing/0001437749-23-031609.json","markdown":"https://secwatch.observer/filing/0001437749-23-031609.md","text":"https://secwatch.observer/filing/0001437749-23-031609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774923031609/0001437749-23-031609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774923031609/crvo20231113_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:35:10.398905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e00043e50dc73cf02bab8f0af2581186d99236ab","claim":"CervoMed Inc. reported financial results for Third Quarter 2023.","evidence_excerpt":"CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study Completed reverse merger; company now publicly traded on Nasdaq ( “ CRVO ” ) CervoMed has cash runway through the end of 2024, by which time the topline primary efficacy results from the Phase 2b RewinD-LB study are expected to be available BOSTON, MA – November 13, 2023 – CervoMed Inc. (NASDAQ: CRVO) , a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced financial results for the third quarter ended September 30, 2023, and provided recent business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774923031609/0001437749-23-031609-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third Quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}